What Ongoing Monitoring After Tysabri PML Involves

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Occupational and Patient Risks

If you or a loved one developed progressive multifocal leukoencephalopathy (PML) after taking Tysabri, you may wonder what happens after stopping the drug. The scientific understanding of PML has evolved through decades of clinical research, and this page summarizes what current studies say about ongoing monitoring and follow-up care.

Medical Evidence and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Washington who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations for filing a claim—is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug 'increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and the expected benefit must be weighed against the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in immunocompromised patients and is caused by the JC virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation can include progressive neurological deficits such as weakness, cognitive decline, vision changes, and speech difficulties. Diagnosis is confirmed through MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The disease usually leads to death or severe disability, and there is no specific antiviral treatment; management focuses on immune reconstitution and supportive care.

Mechanism of Action and Warning Adequacy

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing JC virus to reactivate and cause lytic infection of oligodendrocytes. This immunosuppressive effect is compounded in patients with anti-JCV antibodies, longer treatment duration, or prior immunosuppressant use, as these factors further impair the immune system's ability to control the virus. Regarding the adequacy of warnings, the FDA-approved labeling includes a boxed warning and requires enrollment in the TOUCH Prescribing Program, which mandates that patients read a Medication Guide and understand the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients have developed PML, raising questions about whether the risks were adequately communicated or whether monitoring protocols were followed.

Statute of Limitations for Tysabri Claims in Washington

For affected patients in Washington, settlement-related considerations involve the statute of limitations for filing a claim. In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can vary. PML may develop months to years after starting treatment, and symptoms can be subtle initially. The date of discovery is often when a definitive diagnosis is made, which may be after MRI and CSF analysis. Patients should consult with a legal professional to determine the specific filing deadline based on their individual circumstances. The timeline between exposure and harm is critical for both medical monitoring and legal action. Tysabri is typically administered every four weeks, and PML risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, cases have been reported after shorter durations. Once PML develops, the disease progresses rapidly, often leading to severe disability or death within weeks to months. Early detection and immune reconstitution are essential, but outcomes remain poor.

Summary and Next Steps

In summary, Tysabri-associated PML is a serious adverse event with well-defined risk factors and a clear mechanistic basis. The FDA has mandated warnings and a restricted distribution program, but cases continue to occur. For Washington patients, the statute of limitations for filing a claim is typically three years from discovery of the injury, and the timeline between exposure and harm can vary. Affected individuals should seek both medical and legal advice promptly.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Washington?

In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML, this is often the date of definitive diagnosis. It is important to consult with an attorney to determine the exact deadline based on your specific circumstances.

What are the risk factors for developing PML from Tysabri?

The three main risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the FDA prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Tysabri Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.